Physician profile
Frederick Lim
NPI 1346774775
$4,628.33
in general payments reported to CMS, 2019-2025
25 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $427 · 2023: $1,161 · 2024: $1,592 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,177 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.17 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $729.05 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $636.21 | 2022-2025 | |
| Corcept Therapeutics | $500.83 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.90 | 2022-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $299.41 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $233.38 | 2022-2025 | |
| Abbott Laboratories | $212.89 | 2022-2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $182.09 | 2025 | Twiist |
| Insulet Corporation | $157.65 | 2022-2025 | Omnipod |
| Intuity Medical INC | $146.60 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Medtronic, INC. | $126.87 | 2023-2024 | Minimed 780g, Endoflip |
| Dexcom, INC. | $124.36 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $121.32 | 2022-2025 | Mounjaro, Jardiance |
| Amgen INC. | $120.89 | 2024-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $117.91 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifenet Health | $97.50 | 2024 | Theragenesis Wound Matrix |
| Ibsa Pharma INC. | $93.53 | 2023-2024 | Tirosint, Licart, Licart |
| Recordati_rare_diseases_inc. | $78.53 | 2022-2025 | Isturisa |
| Neurocrine Biosciences, INC. | $53.42 | 2025 | |
| Ascendis Pharma Endocrinology INC | $34.45 | 2025 | Yorvipath |
| Nevro Corp. | $34.06 | 2024 | Senza |
| Ultragenyx Pharmaceutical INC. | $27.51 | 2022 | |
| Beta Bionics, INC. | $23.22 | 2024 | Ilet Bionic Pancreas |
| Kci USA, INC. | $22.79 | 2023 | Prevena |
| Urovant Sciences INC | $19.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.